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Abstract 9 
The evidence base to guide withdrawal of antidementia medications in older people with dementia is limited; 10 
while some randomised controlled studies have considered discontinuation of cholinesterase inhibitors, no such 11 
studies examining discontinuation of the N-Methyl-D-aspartate receptor antagonist memantine have been 12 
conducted to date. The purpose of this opinion article was to summarise the existing evidence on withdrawal of 13 
cholinesterase inhibitors and memantine, to highlight the key considerations for clinicians when making these 14 
prescribing decisions and to offer guidance as to when and how treatment might be discontinued. Until the 15 
evidence-base is enhanced by the findings of large scale randomised controlled discontinuation trials of ChEIs 16 
and memantine which use multiple, clinically relevant cognitive, functional and behavioural outcome measures, 17 
clinicians’ prescribing decisions involve balancing the risks of discontinuation with side-effects and costs of 18 
continued treatment. Such decisions must be highly individualised and patient-centred.  19 
 20 
Key Points 21 
• The evidence base to guide discontinuation of antidementia medications is limited; there is a pressing 22 
need to conduct large scale randomised placebo-controlled discontinuation trials of cholinesterase 23 
inhibitors and memantine 24 
• In the absence of a significant body of evidence, clinicians’ decisions to discontinue an antidementia 25 
medication are highly individualised for each patient, and involve a consideration of risks of 26 
discontinuation versus side-effects and cost of continuing therapy 27 
• If discontinuation is to be attempted, clinicians should taper the dose slowly and carefully monitor the 28 
patient for clear signs of cognitive, functional or behavioural decline. 29 
 30 
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1. Introduction 31 
 32 
Dementia is a global public health concern; it has been estimated that 46.8 million people worldwide were living 33 
with dementia in 2015, and that this number will rise to 74.7 million in 2030 and 131.5 million in 2050 [1]. 34 
Dementia is primarily a condition of old age, its incidence increasing exponentially as age increases [1,2].  35 
Medications approved for the treatment of dementia do not provide a cure; they can only delay disease 36 
progression and alleviate symptoms [3,4]. They comprise cholinesterase inhibitors (ChEIs) and N-methyl-D-37 
aspartate (NMDA) receptor antagonists. Three available ChEIs are widely prescribed in clinical practice: 38 
donepezil, rivastigmine and galantamine. Loss of cholinergic neurons is known to be an early feature in the 39 
pathophysiology of Alzheimer’s disease [5,6]; these agents exert their mechanism of action by preventing 40 
acetylcholine breakdown at synaptic clefts [7]. They have received regulatory approval in Europe and the 41 
United States for treatment of mild - moderate Alzheimer’s disease and, in addition, are approved by the US 42 
Food and Drug Administration for more advanced dementia [8 9]. Drug agencies in other jurisdictions have yet 43 
to approve ChEIs for use in severe Alzheimer’s disease. Rivastigmine is also licensed for treatment of mild to 44 
moderate Parkinson’s Disease dementia in the UK and the USA. Memantine is currently the only NMDA 45 
receptor antagonist available. Licensed for treatment of moderate-severe Alzheimer’s disease in North America, 46 
Europe and Australia [10], its mechanism of action is uncertain, but it is thought to block the excitatory activity 47 
of the toxic neurotransmitter glutamate [11] believed to contribute to the pathogenesis of Alzheimer’s disease 48 
[12] without interfering with the physiological actions required for memory and learning [13, 14]. 49 
 50 
There is uncertainty regarding long-term efficacy of antidementia drugs; most randomized controlled trials 51 
(RCTs) are of no longer than 6 months in duration [15]. However, a number of long-term observational 52 
controlled studies have provided evidence of long-term effects which suggest ChEI treatment should be 53 
continued throughout all stages of Alzheimer’s disease [16,17]. One prospective study of 641 patients conducted 54 
over 20 years reported that a longer, more persistent treatment duration was associated with clinically significant 55 
increased cognitive, global and functional performance [18]. Another prospective study of 790 patients followed 56 
over three years demonstrated that a higher mean ChEI dose was associated with slower functional decline [19]. 57 
 58 
Although long-term ChEI treatment appears to have beneficial effects on global, cognitive and functional 59 
outcomes, it has been associated with adverse events, the consequences of which may be extremely serious for 60 
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this frail patient population. These include gastrointestinal side-effects such as nausea, vomiting and anorexia 61 
[20-22]. Involuntary weight loss has been described in case reports [22], and although subsequent observational 62 
studies suggest that ChEI treatment does not increase risk of weight loss in patients with Alzheimer’s Disease 63 
[23, 24], it has been argued that individual patients may be at risk [25]. There are also concerns that ChEIs may 64 
increase gastric acid production. One cohort study reported that upper gastrointestinal bleeding was not 65 
associated with use of ChEIs [26], but it has again been suggested that this does not mean that individual 66 
patients will not experience these problems if these medications are prescribed [25]. Of particular concern are 67 
the reports of adverse cardiovascular events; prescribing of ChEIs has been reported to be associated with a 68 
statistically significant increased risk of bradycardia leading to hospitalisation, syncope, pacemaker insertion 69 
and hip fracture [27-30]. There have also been case reports of QT interval prolongation with torsade de pointes 70 
ventricular tachycardia [31]. It has therefore been argued that patients taking ChEIs should be asked about 71 
presyncope or syncope and have their pulse examined for bradycardia as a matter of routine [32]. One small 72 
study of hospitalised older people suggested that ChEIs increased the risk of pulmonary disorders [33], although 73 
a much larger population-based study did not demonstrate an increase in serious pulmonary complications in 74 
older people with chronic obstructive pulmonary disease who were also receiving a ChEI [34]. In addition to the 75 
adverse events detailed above, predictable from a knowledge of the pharmacology of ChEIs [25], unpredictable 76 
and rare adverse events have also been reported. One case report has suggested that Pisa syndrome, 77 
characterised by abnormal flexion of the body and head to one side with slight rotation of the trunk, may be 78 
associated with ChEI treatment, although causality remains to be confirmed [35].  79 
 80 
Given the benefits of, and adverse effects associated with, ChEI therapy discussed above, there is considerable 81 
uncertainty among clinicians surrounding how long it should be continued [36], and if and when to discontinue 82 
treatment, particularly as dementia progresses and patients approach end of life [37, ,38]. Some clinical practice 83 
guidelines provide little direction regarding optimal treatment duration and emphasise the modest effects of 84 
currently available drugs [39-41]. Others suggest that ChEIs should be prescribed at all stages of Alzheimer’s 85 
disease, and recommend discontinuation only if there are issues with tolerability or if clinical benefit is no 86 
longer apparent [42-44]. Conversely, however, discontinuation may reduce the risk of adverse events, minimise 87 
polypharmacy, and reduce caregiver burden and cost of care [45]. The clinical picture is further complicated by 88 
reports of discontinuation syndrome on ceasing treatment [46,47].  89 
 90 
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Similarly, there is limited evidence regarding long-term efficacy of memantine [48]. Most trials have utilised 91 
durations ranging from 12 weeks to 6 months [49-55], although several follow-up and open-label extension 92 
studies have reported clinically relevant benefits for patients treated for one or two years [10,56]. There is 93 
uncertainty over efficacy in end-stage dementia [57] and when to discontinue treatment [48]. Prolonged 94 
treatment is not without risks; there have been case reports of serious adverse effects, including loss of 95 
consciousness and/or seizure-like episodes [58]. Discontinuation of memantine, as with ChEIs, may minimise 96 
polypharmacy and reduce caregiver burden, cost of care and the risk of adverse events. This uncertainty serves 97 
to make clinical decisions regarding discontinuing memantine complex.   98 
 99 
In this article we will examine the evidence base available to guide withdrawal of antidementia agents, 100 
highlighting the key considerations for clinicians when making prescribing decisions. We will offer guidance to 101 
support clinicians in making these decisions, based on the currently available evidence, and will discuss research 102 
priorities for future work in this area. 103 
 104 
2. Search Methodology 105 
 106 
A literature search was conducted using MEDLINE (1950–April 2016), EMBASE (1980– April 2016), Web of 107 
Science (1981– April 2016), International Pharmaceutical Abstracts (1970– April 2016) and the Cochrane 108 
Library of Systematic Reviews (1999–April 2016). The search terms used were ‘cholinesterase inhibitor(s ’, 109 
‘acetylcholinesterase inhibitor(s)’, ‘donepezil’, ‘rivastigmine’, ‘galantamine’, ‘NMDA receptor antagonist’, 110 
‘memantine’, ‘discontinue’, ‘discontinuation’, ‘withhold(ing)’, ‘withheld’, ‘withdraw’, ‘withdrawal’, 111 
‘cessation’, ‘reducing’, ‘tapering’, ‘stopping’, ‘dementia’,  ‘older’, ‘old’, ‘elderly’, ‘aged’ and combinations 112 
thereof. Only articles in the English language were selected. No attempt was made to reject papers on the basis 113 
of methodology, e.g. not a randomized controlled trial, as some studies were descriptive in nature or were papers 114 
that were classified as commentaries. One hundred and sixteen references have been included in this paper. 115 
 116 
3. Discontinuing cholinesterase inhibitors 117 
 118 
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To date there has been limited research into whether discontinuation of antidementia medications leads to 119 
clinically significant cognitive and behavioural decline [41]. This is, however, gaining research interest, 120 
illustrated by the increasing numbers of RCTs in recent years detailed in Table 1. 121 
 122 
INSERT TABLE 1 HERE  123 
 124 
It must be noted that the trials summarised in Table 1 examined ChEIs, not memantine, and that duration of 125 
ChEI therapy prior to randomisation varied significantly. Furthermore, the majority of these studies were funded 126 
by the pharmaceutical industry, which must be borne in mind when interpreting the findings. The authors of 127 
these studies varied in their recommendations; Holmes et al. reported that discontinuation of ChEI treatment 128 
may lead to behavioural decline [59]. Johannsen et al. suggested that patients may benefit from continued 129 
therapy and that decisions to discontinue ChEIs should be carefully considered, based on evaluations of the 130 
impact on multiple symptom domains and not on cognition alone [60]. They argued that decline may not 131 
necessarily reflect lack of benefit, as the decline observed may be less than that which would have occurred 132 
without treatment, and that discontinuation may be counter-productive given the potential for loss of therapeutic 133 
response during washout between treatments. 134 
 135 
The authors of the DOMINO-AD trial concluded that perceived benefits of continuing treatment are unclear, but 136 
consideration of the potential risks of withdrawal should inform clinicians’ decisions [61]. Gaudig et al. argued 137 
that their findings corroborated previous work suggesting that long-term galantamine treatment may delay time 138 
to nursing home placement [63,83]. They concluded that sustained, uninterrupted therapy yielded clinical 139 
benefits; over the course of two 6-week withdrawal studies, patients continuing galantamine maintained the 140 
improvements in cognitive function they exhibited in the original parent studies. Scarpini et al. [64] 141 
acknowledged that the analysis of their primary cognitive outcome measure, the ADAS-cog/11, was 142 
underpowered, but argued that their data provided supporting evidence that galantamine is well tolerated when 143 
used long-term and that treatment should be continued in patients observed to benefit from galantamine therapy. 144 
They concluded that interruption of therapy should be undertaken with caution and that treatment should only be 145 
discontinued in the event of adverse effects. 146 
 147 
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A recent meta-analysis of studies investigating ChEI discontinuation in patients with Alzheimer’s disease [84] 148 
included five of the studies described above [59-61,63,64]. Data from cognitive outcome measures were 149 
extracted from all included studies; ADAS-cog/11 scores were converted to MMSE scores. Neuropsychiatric 150 
symptoms, measured using the NPI, were extracted for three of the included studies [59-61]. Quality of included 151 
studies was analysed using items from the Newcastle-Ottawa Scale [85] and the Cochrane Collaboration’s risk 152 
of bias assessment tool [86 ]. The authors reported that patients discontinuing ChEIs demonstrated significant 153 
worsening of cognition from baseline to the endpoint of the study compared to those continuing treatment. They 154 
reported no significant heterogeneity or publication bias. For the studies reporting neuropsychiatric outcomes, 155 
patients discontinuing ChEIs demonstrated worsening of neuropsychiatric symptoms, again with no significant 156 
heterogeneity or publication bias. Adverse event incidence and study dropout were similar between continuation 157 
and discontinuation groups. The authors suggested that the deteriorations in cognition and neuropsychiatric 158 
symptoms may have clinical relevance and are important considerations for clinicians when deciding whether to 159 
discontinue therapy. They stressed the highly individualised nature of this decision, suggesting that factors such 160 
as side-effects, current cognitive and functional status and caregiver preference must be considered. 161 
 162 
Most recently, the pilot trial conducted by Herrmann et al. reported no significant differences in CGI-C score 163 
[71] between continuation and placebo groups in the occurrence of adverse events, or in any of the secondary 164 
outcome measures, suggesting that ChEI discontinuation does not result in clinical worsening, and is safe and 165 
well-tolerated in institutionalized patients with moderate to severe dementia who have been treated for at least 166 
two years [45]. The results of this pilot trial did not replicate the findings of the DOMINO-AD trial [61]; 167 
treatment allocation was not observed to have a significant effect on change in cognition, function or global 168 
status over the eight-week study period. The authors suggested that this may be due to differences in setting and 169 
participant characteristics, and acknowledged that the study was underpowered to detect a difference in CGI-C; 170 
clinical deterioration in the discontinuation group was numerically greater than in the continuation group and the 171 
authors argued that statistically significant differences may have been detected with a larger sample size, though 172 
they speculated as to the clinical relevance of such a difference. They observed that baseline scores of psychosis 173 
correlated with clinical worsening when ChEIs were discontinued, and suggested that clinicians should closely 174 
monitor patients with psychotic symptoms when attempting discontinuation.  175 
 176 
7 
 
These trials, outlined above and in Table 1, add to the evidence base which includes studies employing other 177 
design methodologies; Daiello et al. undertook a retrospective cohort study of 178 nursing home residents with a 178 
diagnosis of Alzheimer’s or non-Alzheimer’s dementia, treated with ChEIs [87]. The cohort was divided into a 179 
continuation group, who were prescribed continuous ChEI therapy for ˃ 9 months, and a discontinuation group 180 
(for whom there were no prescription claims for ChEIs for a minimum of 60 days after a stable regimen of 181 
treatment). Each patient who discontinued therapy was matched with ≥ 1 member of the continuation cohort. 182 
The primary outcome measures were change in total Depression Rating Scale (DRS) [88] and Aggressive 183 
Behavior Scale (ABS) [89] between baseline and the last Minimum Data Set (MDS) assessment. The authors 184 
reported that behavioural worsening, demonstrated by an increase in the mean change in ABS score, occurred in 185 
the discontinuation cohort but not in the continuation cohort, and that the difference between groups was 186 
statistically significant. There was no significant difference between continuation and discontinuation cohorts in 187 
change in mood symptoms on the DRS. Analysis of secondary outcomes indicated that patients in the 188 
discontinuation group exhibited significantly more episodes of repetitive questioning and repetitive health 189 
complaints and spent significantly less time in leisure-related activities than patients in the continuation cohort. 190 
These findings must be interpreted in light of the retrospective nature of the study and the limitations in the data 191 
set; it was not possible to determine reasons for discontinuation or rule out discontinuation due to an accelerated 192 
worsening of symptoms. 193 
 194 
Attitudes of prescribers to discontinuing ChEIs have also been examined. Herrmann et al. conducted an online 195 
survey of geriatric psychiatrists, neurologists, and geriatricians (n=27) to determine opinions and consensus 196 
regarding circumstances in which ChEIs should be discontinued [90], the majority of whom agreed or strongly 197 
agreed that ChEIs should be discontinued if requested by a patient (with capacity) or a substitute decision-maker 198 
(if the patient is not considered to have capacity), or in the presence of severe adverse events. There was greater 199 
uncertainty on issues related to effectiveness, particularly regarding what constituted “greater than expected 200 
decline”. Clinicians were reluctant to base decisions on any single measure of cognition, behaviour or function; 201 
the MMSE in particular was perceived to be of little value. Studies considering medication appropriateness have 202 
employed Delphi consensus methods to determine clinician opinion. Farrell et al. defined ChEIs as a drug class 203 
in need of evidence-based guidelines for deprescribing, arguing that in many cases a specialist initiates 204 
treatment, and a primary care practitioner has little guidance on how to determine ongoing need [91]. Consensus 205 
panels of experts in US [92] and UK [93] studies considered ChEIs to be “never appropriate” or “rarely 206 
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appropriate” for people with advanced dementia and a short life expectancy, respectively. A recent Delphi panel 207 
study in Canada did not reach a consensus regarding ChEI appropriateness in severe dementia [94], reflecting 208 
continued uncertainty, which is also evident in the variation of prescribing rates. A number of studies have 209 
reported that ChEIs are prescribed for between 7 % and 36% of people with severe dementia in the US and 210 
Europe [95 -97]. 211 
 212 
4. Discontinuing memantine 213 
 214 
To the best of the author’s knowledge, no randomised controlled studies have been published to date which 215 
examine memantine discontinuation. A small pilot study into the safety and tolerability of memantine in 216 
Parkinson’s Disease Dementia reported a slightly greater deterioration in cognitive function six weeks after 217 
discontinuation (assessed using the Dementia Rating Scale [98]) when compared with placebo, though this was 218 
not statistically significant [99]. When global outcomes were examined using CIBIC-Plus [72], significantly 219 
more patients taking memantine deteriorated compared to those treated with placebo, and the magnitude of this 220 
deterioration was significantly greater, demonstrated by a significantly higher CIBIC-Plus score, suggesting that 221 
continued treatment with memantine may be needed to maintain global level of functioning. Fillit et al. 222 
conducted a retrospective chart review of 113 nursing home residents to examine the effect of memantine 223 
discontinuation, and reported significant worsening of overall health status for patients in whom memantine was 224 
stopped, compared to those treated continuously [100]. They reported an average emergence of approximately 1 225 
to 2 new symptoms, or worsening of 3 to 4 existing symptoms, within 2 to 3 months of discontinuation for each 226 
patient who discontinued memantine treatment, compared with continuously treated patients, and suggested that 227 
the negative effects of discontinuation may increase over time. An extension trial of memantine in dementia 228 
with Lewy Bodies and Parkinson’s disease dementia reported that recurrence of symptoms occurred more 229 
frequently upon drug withdrawal in patients receiving memantine than in those taking placebo, with significant 230 
global deterioration measured by the CGI-C [101]. The authors suggested that treatment-associated benefits are 231 
rapidly lost following memantine withdrawal. 232 
Despite these findings, and due to the lack of RCTs in this area, there remains uncertainty over when to 233 
discontinue treatment [48] and over efficacy in end-stage dementia [57]. This is reflected in the Delphi 234 
consensus studies considering medication appropriateness, in which memantine has been categorised as “never 235 
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appropriate” [92] or “sometimes appropriate” [93] for people with advanced dementia and a short life 236 
expectancy. In a further study, no consensus was reached regarding appropriateness in severe dementia [94].  237 
 238 
5. Guidance for discontinuation of antidementia medications in clinical practice 239 
Clinicians who provide care for people with dementia are faced with the complex task of attempting to 240 
extrapolate this limited and somewhat contradictory evidence base to the individual patient presenting for 241 
treatment [102]. Decisions to cease treatment are further complicated by the view (albeit held by a minority) that 242 
cholinesterase inhibitors and memantine may have neuroprotective or disease-modifying effects [103-108]. The 243 
American Geriatrics Society Choosing Wisely Workgroup suggests that clinicians should consider ChEI 244 
discontinuation if the cognitive, behavioural and functional goals of treatment are not met [109]. Other guidance 245 
suggests determining benefit by considering whether treatment meets goals based on symptoms that patients and 246 
their families define as important [102, 110]. This highly individualised, patient-centred approach has been 247 
advocated by others [25,60,84]. Hogan suggested that treatment benefit may manifest only as a slowed 248 
progression, and that this should be considered by physicians when deciding whether to discontinue treatment 249 
[25]. A recent consensus conference in Canada noted that discontinuing ChEIs may lead to worsening cognition 250 
and function, and recommended that risks should be balanced with known side-effects and costs of continuing 251 
treatment [43]. The circumstances in which treatment should be discontinued have been described as follows 252 
[43,90,111]: 253 
 254 
1. When the patient/caregiver decides to stop (after being advised on the risks and benefits of stopping 255 
treatment 256 
2. When the patient refuses to take the medication 257 
3. When there are issues with patient compliance which cannot be reasonably resolved 258 
4. When the patient’s cognitive, functional or behavioural decline is worse on treatment  259 
5. When there are intolerable side-effects likely to be caused by the ChEI 260 
6. When comorbidities make treatment risky or futile (for example, terminal illness) 261 
7. Where there is no clinically meaningful benefit to continuing therapy. 262 
8. When dementia has progressed to a severely impaired stage (Global Deterioration Scale stage 7, 263 
development of swallowing difficulties. 264 
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 265 
The authors of these guidelines acknowledge the difficulties in determining if an adverse event is related to the 266 
treatment and in determining lack of clinically relevant benefit in this population; they suggest that an 267 
assessment of the probability that the adverse event is related to the ChEI [112] is necessary, although the 268 
difficulties in applying criteria developed for this purpose to older people with adverse drug reactions, and the 269 
lack of a method validated specifically for use in older people with multiple co-morbidities and medications, 270 
complicate this assessment [113]. The authors further recommend that clinical judgement should form the basis 271 
of determining lack of benefit rather than ceasing treatment when a patient reaches a certain score on a cognitive 272 
outcome or when they are institutionalised [57,114]. Many outcome measures used in studies of antidementia 273 
medications have limitations; the MMSE, although simple to administer in clinical practice, lacks sensitivity in 274 
determining rate of change in cognition and progression to severe dementia [115,116]; the ADAS-cog scale 275 
appears to be more sensitive to change but is more time-consuming to administer [4]. In addition to measures of 276 
cognitive function, functional abilities and behavioural and psychological symptoms should be considered, and 277 
an overall assessment of severity using the global deterioration scale (GDS) or functional assessment staging 278 
(FAST) undertaken to monitor disease progression and to determine treatment discontinuation [4,57].  Such an 279 
individualised approach should also monitor patients’ specific sets of symptoms and considers management 280 
goals and potential benefits when deciding on discontinuation. 281 
 282 
When a decision is made to stop therapy, tapering of the dose and monitoring the patient for evidence of 283 
significant decline during the next 1 – 3 months have been advocated [25,43,45,84]. If such decline occurs, 284 
reinstatement of therapy should be considered. 285 
 286 
Although no such guidance is available to support clinicians to discontinue memantine, the circumstances in 287 
which treatment should be stopped, and the caution to be exercised in terms of dose tapering and monitoring 288 
patients for significant decline, are similar.  289 
 290 
6. Future research priorities 291 
 292 
Clinical practice guidelines should be based on controlled discontinuation trials [90]. While some small scale 293 
studies examining discontinuing ChEIs have been conducted, there is a pressing need for large-scale double-294 
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blind RCTs examining the impact of discontinuing these medications on multiple clinically relevant cognitive, 295 
functional and behavioural outcomes for patients. Furthermore, to the best of the author’s knowledge, no such 296 
studies examining discontinuation of memantine exist. The evidence-base for discontinuing memantine requires 297 
significant research attention. 298 
 299 
7. Conclusion 300 
 301 
This article examines the limited evidence base available to guide withdrawal of antidementia agents and 302 
highlights the pressing need for large scale randomised controlled discontinuation trials which use multiple, 303 
clinically relevant cognitive, functional and behavioural outcome measures. Until the evidence-base is enhanced 304 
by the findings of such studies, clinicians’ prescribing decisions involve balancing risks of discontinuation with 305 
side-effects and costs of continued treatment. Such decisions must be highly individualised and patient-centred. 306 
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Author/Year ChEI studied Duration of 
ChEI 
therapy prior 
to 
withdrawal 
study 
Sample  Design Outcome Measures Study Findings Study funder 
Holmes et al. 
2004 [59] 
Donepezil 3 mo Community-dwelling 
patients with mild-
moderate AD 
exhibiting marked 
neuropsychiatric 
symptoms.  
Age ≥ 55y, 
NINCDS-ADRDA 
probable or possible 
AD ≥ 6 mo duration, 
MMSE 11 -27  
24- week double-
blind placebo-
controlled 
withdrawal study. 
Patients treated with 
5 mg/day donepezil 
for 6 weeks followed 
by 10 mg/day for 6 
weeks in open label 
phase, before being 
randomised to 
placebo (n=55) or 10 
mg/day (n=41) for 6 
weeks. If no marked 
cognitive 
deterioration 
observed (loss of > 2 
points on MMSE 
compared with 
baseline), treatment 
was continued for a 
further 6 weeks. 
Primary measure: 
NPI 
Secondary 
measure: NPI-D 
Patients who 
discontinued 
donepezil 10 mg 
following open label 
treatment 
demonstrated 
significant worsening 
of NPI and NPI-D 
scores compared to 
continued 
improvements in 
patients continuing 
treatment; the 
difference in NPI 
scores between 
discontinuation and 
continuation groups 
was maintained at 6.2 
points at weeks 6 and 
12. NPI-D scores 
showed a consistent 
difference of 2.7 
points and 2.8 points 
at weeks 6 and 12 
respectively.  
Although statistically 
significant, these 
differences were not 
considered clinically 
significant. 
Pfizer/Eisai 
Johannsen et al. Donepezil 3-6 mo Outpatients with 12-week double- Primary measure: Statistically Pfizer/Eisai 
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2006 [60] mild-moderate AD 
for whom clinical 
benefit initially 
uncertain 
Age ≥ 50y, DSM-IV 
and NINDS-
ADRDA probable or 
possible AD, MMSE 
10-26 
blind placebo-
controlled 
withdrawal study. 
Patients taking 
donepezil 10 mg/day 
during open- label 
study were 
randomised to 
continue donepezil 
(n=99) or were 
switched to placebo 
(n=103), for 12 
weeks. 
ADAS-cog/11 
Secondary 
measures MMSE, 
NPI, DAD 
 
significant worsening 
of MMSE (1.13 
points, p=0.02) and 
NPI (3.16 points, 
p=0.02) in patients 
discontinuing 
donepezil. Differences 
were less than MCIDs 
for MMSE and NPI. 
No significant 
differences observed 
in ADAS-cog/11 
(0.57, p=0.5) or DAD 
(3.67, p=0.1).   
 
Howard et al 
2012, 2015 
[61,62] 
Donepezil At least 3 
mo 
Community-dwelling 
patients with 
moderate-severe AD. 
NINDS-ADRDA 
probable or possible 
AD, MMSE 5-13 
Multicentre double-
blind randomised 
placebo-controlled 
trial. Patients 
randomised to 
continue donepezil 
10 mg/day (n=73) or 
were switched to 
placebo (n=73) for 52 
weeks 
Primary measures: 
SMMSE, BADLS 
Secondary 
measures: NPI, 
DEMQOL-Proxy, 
GHQ-12 
(caregiver); risk of 
nursing home 
placement 
Significant worsening 
of cognition and 
function in patients for 
whom donepezil was 
withdrawn. Patients 
assigned to continue 
donepezil had higher 
SMMSE scores by an 
average of 1.9 points 
and lower BADLS 
scores by an average 
of 3.0 points (p<0.001 
for both comparisons). 
The difference in 
cognitive function 
exceeded the MCID of 
1.4 points on the 
SMMSE), but the 
difference in BADLS 
did not exceed the 
MCID of 3.5 points. 
Differences in NPI, 
DEMQQOL-Proxy 
and GHQ-12 scores 
UK Medical 
Research Council 
and the 
Alzheimer’s 
Society 
21 
 
for patients continuing 
vs patients 
discontinuing 
donepezil were not 
statistically 
significant. Donepezil 
withdrawal associated 
with increased risk of 
nursing home 
placement during the 
12 month treatment 
period, but no 
significant difference 
in institutionalisation 
risk during subsequent 
36 month follow-up. 
Gaudig et al 2011 
[63] 
Galantamine 3 mo Outpatients with 
mild-moderate AD. 
NINDS-ADRDA 
probable AD 
Study 1: MMSE 10- 
22 and a score of 
≥18 on the ADAS-
cog/11 
Study 2: MMSE 11-
24 and score of ≥2 
on ADAS-cog 
Double-blind 
withdrawal studies 
including patients 
who had completed a 
previous 3-month or 
5-month randomised 
clinical trial 
investigating the 
safety and efficacy of 
galantamine [65,66]. 
In study 1 [65], 
patients taking 
placebo (n=219), 8 
mg/day galantamine 
(n=104) or 16 
mg/day galantamine 
(n=202) continued 
the assigned 
treatment for 6 
weeks. Patients 
taking 24mg/day 
galantamine had 
active treatment 
Primary measure: 
ADAS-cog/11 
Secondary 
measures: safety 
and tolerability 
assessments 
For patients in whom 
cognition improved 
with galantamine 
treatment, withdrawal 
was associated with 
cognitive decline. Six 
weeks after stopping 
treatment, the 
cognitive function of 
these patients had 
deteriorated towards 
levels observed in 
patients who had 
received continuous 
placebo. In study 1, 
patients continuously 
treated with 
galantamine 16 
mg/day demonstrated 
a mean improvement 
of 0.6 points in 
ADAS-cog/11 
(p=0.451) compared 
Janssen 
Pharmaceutica 
NV, Janssen 
EMEA Medical 
Affairs 
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discontinued and 
received placebo for 
6 weeks (n=198). In 
study 2 [66], patients 
receiving placebo in 
the parent trial 
continued placebo for 
6 weeks (n=47), and 
those taking 24 
mg/day or 32 mg/day 
galantamine were 
randomised to a 
withdrawal group and 
received placebo for 
6 weeks (n=39), or a 
continuation group in 
which galantamine 
was continued at the 
dose assigned in the 
parent trial (n=32). 
to the baseline of the 
parent trial, while 
patients who had 
received continuous 
placebo demonstrated 
a 2.9 point 
deterioration in 
ADAS-cog/11 
(p=0.003). Patients 
switched from 
galantamine to 
placebo demonstrated 
a statistically 
significant 
deterioration of 2.4 
points (p=0.001). 
These differences 
were less than the 
MCID of 4 points. In 
study 2, patients who 
had received 
continuous 
galantamine exhibited 
a mean improvement 
of 1.5 points in 
ADAS-cog/11 
(p=0.187), while 
patients who had 
switched from 
galantamine to 
placebo or who had 
received continuous 
placebo demonstrated 
mean deteriorations of 
0.1 (p=0.968) and 0.9 
(p=0.366) 
respectively, Again, 
these differences were 
less than the MCID. 
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Scarpini et al 2011 
[64] 
Galantamine 12 mo Outpatients with 
mild-moderate AD 
Age ≥50 y, NINDS-
ADRDA probable or 
possible AD, MMSE 
11-24, no decline of 
< 4 points following 
open-label phase  
Randomised, double-
blind placebo-
controlled trial. 
Patients randomised 
to continue 16 
mg/day galantamine 
(n=76) or to 
discontinue active 
treatment and take 
placebo (n=63) for up 
to 24 months 
Primary measure: 
time to 
deterioration 
(deterioration in 
ADAS-cog/11 
score of ≥ 4 points) 
Secondary efficacy 
measures: CIBIC-
plus scores, safety 
and tolerability 
assessments 
Patients who 
responded to 
galantamine in the 
open-label phase of 
the study and in whom 
treatment was 
continued were less 
likely to discontinue 
the study prematurely 
for any reason or due 
to lack of efficacy 
than patients in whom 
galantamine was 
discontinued. Patients 
taking placebo were 
more likely to 
discontinue treatment 
prematurely than those 
taking galantamine for 
any reason (HR 1.76, 
95% CI 1.10-2.81, 
p=0.02) or lack of 
efficacy (HR 1.80, 
95% CI 1.02-3.18, 
p=0.04); no 
statistically significant 
difference was 
observed for change in 
ADAS-cog ≥ 4 
between treatment 
groups (HR 1.66, 95% 
CI 0.78-3.54, p=0.19) 
Janssen Cilag 
GmbH/ Janssen 
EMEA 
Herrmann et al 
2016 [45] 
Donepezil, 
galantamine or 
rivastigmine 
(oral) 
At least 2y Patients with 
moderate to severe 
AD residing in long-
term care 
Age ≥ 55y, NINDS-
ADRDA probable 
AD, DSM-IV criteria 
8-week randomised, 
double-blind 
placebo-controlled 
pilot trial. Patients 
were randomised 
with a 1:1 ratio 
balanced by ChEI to 
Primary measure: 
CGI-C 
Secondary 
measures: 
cognitive function 
(SMMSE, SIB), 
behavioural status 
No significant 
difference in CGI-C 
score, adverse events 
or any secondary 
outcome measure, 
between continuation 
and placebo groups 
Alzheimer’s 
Society of 
Canada/Coleman 
Fund (internal 
funding) 
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for primary 
degenerative 
dementia, SMMSE 
score ≤ 15 
continue receiving 
their ChEI (n=21) at 
their current dose, or 
to receive placebo 
(discontinuation; 
n=19). Patients 
discontinuing were 
tapered off ChEIs 
over 2 weeks and 
then continued on 
placebo for a further 
6 weeks  
(NPI-NH, CMAI, 
AES), function 
(ADCS-ADL-sev), 
quality of life 
(QUALID), safety 
and tolerability 
 721 
Abbreviations: AD Alzheimer’s Disease, ADAS-cog/11 Alzheimer's Disease Assessment Scale cognitive subscale [67], ADCS-ADL-sev Alzheimer's Disease Cooperative 722 
Study-Activities of Daily Living-severe [68], AES Apathy Evaluation Scale [69], BADLS Bristol Activities of Daily Living Scale [70], CGI-C Clinician’s Global Impression 723 
of Change [71], ChEI Cholinesterase inhibitor, CI Confidence Interval, CIBIC-plus Clinician's Interview-Based Impression of Change Plus Caregiver Input [72] CMAI 724 
Cohen-Mansfield Agitation Inventory [73], DAD Disability Assessment for Dementia [74], DEMQOL-Proxy assessment of health-related quality of life by caregiver [75], 725 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, GHQ-12 General Health Questionnaire (caregiver) [76], HR Hazard Ratio, MCID Minimum 726 
Clinically Important Difference, mo month, MMSE Mini Mental State Examination [77], NINDS-ADRDA National Institute of Neurologic and Communicative Disorders 727 
and Stroke/Alzheimer’s Disease and Related Disorders Association, NPI Neuropsychiatric Inventory ) [78] , NPI-D Neuropsychiatric Inventory-Distress ) [78],  QUALID 728 
Quality of Life in Late-Stage Dementia [79] , SIB Severe Impairment Battery [80], SMMSE Standardised Mini Mental State Examination [81,82], y year 729 
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